ChemoMetec Completes Acquisition of Ovizio Imaging Systems
ChemoMetec A/S is excited to announce the successful closing of its acquisition of Ovizio Imaging Systems SA. This significant step forward affirms the commitment of ChemoMetec to expand its capabilities and product offerings in the biotechnology sector.
Overview of the Acquisition
With all capital owners accepting ChemoMetec’s takeover offer, the acquisition of 100% of Ovizio Imaging Systems has been completed for a total purchase price of EUR 2,830,000. This acquisition marks a strategic investment for ChemoMetec, combining innovations in cell counting and bioprocess analytics.
What Ovizio Brings to the Table
Ovizio Imaging Systems specializes in developing advanced cell counting technology based on holographic microscopy. Their primary product is designed for use in bioprocessing, along with applications in cell and gene therapy. This innovative cell counter is uniquely integrated with customer bioreactors through a disposable, sterilized item, ensuring high cleanliness standards.
Operational Benefits of the Acquisition
The technology from Ovizio permits continuous cell extraction from bioreactors, allowing detailed analyses and prompt return of cells to their original environment. This process not only enhances efficiency but also supports rigorous quality control practices demanded within the pharmaceutical and biotech sectors.
Financial Impact and Market Presence
In the previous fiscal year, Ovizio reported revenues of EUR 1.4 million, largely driven by sales of consumables and service contracts. The integration of Ovizio into ChemoMetec’s broader operational framework is anticipated to bolster revenue streams and enhance customer offerings across the board.
About ChemoMetec A/S
Founded in 1997 and publicly traded on Nasdaq OMX Copenhagen, ChemoMetec A/S has established itself as a leader in the manufacturing and marketing of instruments for cell counting and a variety of other measurements. Their products are extensively used within the pharmaceutical, biotech, and agricultural industries, and they serve numerous prominent customers worldwide.
Looking Ahead
The successful acquisition underscores ChemoMetec's strategic objectives to innovate and expand its product portfolio. As the biotech industry continues to evolve, ChemoMetec is poised to leverage Ovizio’s advanced technologies to enhance its market position and drive growth.
Contact Information
For additional information about this acquisition or ChemoMetec’s product offerings, please reach out to:
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
Frequently Asked Questions
What is the significance of ChemoMetec acquiring Ovizio Imaging Systems?
This acquisition allows ChemoMetec to enhance its capabilities in cell counting and bioprocessing, strengthening its market position in biotechnology.
How will this acquisition impact ChemoMetec's revenue?
Integrating Ovizio’s technology and product offerings is expected to boost revenue through enhanced sales and service contracts.
What technology does Ovizio Imaging Systems provide?
Ovizio specializes in holographic microscopy for advanced cell counting and bioprocess analytics, facilitating near-continuous processes in biopharmaceutical settings.
When was ChemoMetec founded?
ChemoMetec was founded in 1997 and has grown into a key player in the cell counting technology sector.
Who are ChemoMetec's primary customers?
The primary customers of ChemoMetec include leaders in the pharmaceutical and biotech industries, who rely on their advanced measurement solutions.
